These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 11754579)

  • 1. New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones.
    Brea J; Rodrigo J; Carrieri A; Sanz F; Cadavid MI; Enguix MJ; Villazón M; Mengod G; Caro Y; Masaguer CF; Raviña E; Centeno NB; Carotti A; Loza MI
    J Med Chem; 2002 Jan; 45(1):54-71. PubMed ID: 11754579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformationally constrained butyrophenones with affinity for dopamine (D(1), D(2), D(4)) and serotonin (5-HT(2A), 5-HT(2B), 5-HT(2C)) receptors: synthesis of aminomethylbenzo[b]furanones and their evaluation as antipsychotics.
    Raviña E; Casariego I; Masaguer CF; Fontenla JA; Montenegro GY; Rivas ME; Loza MI; Enguix MJ; Villazon M; Cadavid MI; Demontis GC
    J Med Chem; 2000 Nov; 43(24):4678-93. PubMed ID: 11101359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformationally constrained butyrophenones with mixed dopaminergic (D(2)) and serotoninergic (5-HT(2A), 5-HT(2C)) affinities: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and -thienocycloalkanones as putative atypical antipsychotics.
    Raviña E; Negreira J; Cid J; Masaguer CF; Rosa E; Rivas ME; Fontenla JA; Loza MI; Tristán H; Cadavid MI; Sanz F; Lozoya E; Carotti A; Carrieri A
    J Med Chem; 1999 Jul; 42(15):2774-97. PubMed ID: 10425088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformationally constrained butyrophenones as new pharmacological tools to study 5-HT 2A and 5-HT 2C receptor behaviours.
    Brea J; Masaguer CF; Villazón M; Cadavid MI; Raviña E; Fontaine F; Dezi C; Pastor M; Sanz F; Loza MI
    Eur J Med Chem; 2003 Apr; 38(4):433-40. PubMed ID: 12750032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist.
    Dunlop J; Watts SW; Barrett JE; Coupet J; Harrison B; Mazandarani H; Nawoschik S; Pangalos MN; Ramamoorthy S; Schechter L; Smith D; Stack G; Zhang J; Zhang G; Rosenzweig-Lipson S
    J Pharmacol Exp Ther; 2011 Jun; 337(3):673-80. PubMed ID: 21402690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. m-CPP hypolocomotion is selectively antagonized by compounds with high affinity for 5-HT(2C) receptors but not 5-HT(2A) or 5-HT(2B) receptors.
    Gleason SD; Lucaites VL; Shannon HE; Nelson DL; Leander JD
    Behav Pharmacol; 2001 Dec; 12(8):613-20. PubMed ID: 11856898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists.
    Vickers SP; Easton N; Malcolm CS; Allen NH; Porter RH; Bickerdike MJ; Kennett GA
    Pharmacol Biochem Behav; 2001; 69(3-4):643-52. PubMed ID: 11509227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
    Knight AR; Misra A; Quirk K; Benwell K; Revell D; Kennett G; Bickerdike M
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug; 370(2):114-23. PubMed ID: 15322733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling.
    Rashid M; Manivet P; Nishio H; Pratuangdejkul J; Rajab M; Ishiguro M; Launay JM; Nagatomo T
    Life Sci; 2003 May; 73(2):193-207. PubMed ID: 12738034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
    Millan MJ; Mannoury la Cour C; Chanrion B; Dupuis DS; Di Cara B; Audinot V; Cussac D; Newman-Tancredi A; Kamal M; Boutin JA; Jockers R; Marin P; Bockaert J; Muller O; Dekeyne A; Lavielle G
    J Pharmacol Exp Ther; 2012 Mar; 340(3):750-64. PubMed ID: 22178752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.
    Andrés JI; Alcázar J; Alonso JM; Díaz A; Fernández J; Gil P; Iturrino L; Matesanz E; Meert TF; Megens A; Sipido VK
    Bioorg Med Chem Lett; 2002 Jan; 12(2):249-53. PubMed ID: 11755365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different regulation of rat 5-HT(2A) and rat 5-HT(2C) receptors in NIH 3T3 cells upon exposure to 5-HT and pipamperone.
    Oekelen DV; Jurzak M; Van de Wiel D; Van Hecke G; Luyten WH; Leysen JE
    Eur J Pharmacol; 2001 Aug; 425(1):21-32. PubMed ID: 11672571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of 5-HT(2A) and 5-HT(2C) receptor binding affinities of novel pyrimidine derivatives.
    Bózsing D; Simonek I; Simig G; Jakóczi I; Gacsályi I; Lévay G; Tihanyi K; Schmidt E
    Bioorg Med Chem Lett; 2002 Nov; 12(21):3097-9. PubMed ID: 12372510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (1R, 3S)-(-)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity.
    Booth RG; Fang L; Huang Y; Wilczynski A; Sivendran S
    Eur J Pharmacol; 2009 Aug; 615(1-3):1-9. PubMed ID: 19397907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.
    Andrés JI; Alcázar J; Alonso JM; Díaz A; Fernández J; Gil P; Iturrino L; Matesanz E; Meert TF; Megens A; Sipido VK
    Bioorg Med Chem Lett; 2002 Jan; 12(2):243-8. PubMed ID: 11755364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands.
    Chambers JJ; Parrish JC; Jensen NH; Kurrasch-Orbaugh DM; Marona-Lewicka D; Nichols DE
    J Med Chem; 2003 Jul; 46(16):3526-35. PubMed ID: 12877591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential regulation of rat peripheral 5-HT(2A) and 5-HT(2B) receptor systems: influence of drug treatment.
    Enguix MJ; Sánchez L; Villazón M; Brea J; Tristán H; Caruncho HJ; Cadavid MI; Loza MI
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Aug; 368(2):79-90. PubMed ID: 12861437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.
    Thomsen WJ; Grottick AJ; Menzaghi F; Reyes-Saldana H; Espitia S; Yuskin D; Whelan K; Martin M; Morgan M; Chen W; Al-Shamma H; Smith B; Chalmers D; Behan D
    J Pharmacol Exp Ther; 2008 May; 325(2):577-87. PubMed ID: 18252809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the contractile 5-hydroxytryptamine receptor in the renal artery of the normotensive rat.
    Watts SW; Thompson JM
    J Pharmacol Exp Ther; 2004 Apr; 309(1):165-72. PubMed ID: 14724222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Butyrophenone analogues in the carbazole series as potential atypical antipsychotics: synthesis and determination of affinities at D(2), 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
    Masaguer CF; Raviña E; Fontenla JA; Brea J; Tristán H; Loza MI
    Eur J Med Chem; 2000 Jan; 35(1):83-95. PubMed ID: 10733606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.